|Bid||128.48 x 800|
|Ask||128.50 x 1200|
|Day's Range||127.93 - 129.29|
|52 Week Range||118.62 - 148.99|
|Beta (3Y Monthly)||0.62|
|PE Ratio (TTM)||225.06|
|Earnings Date||Apr 16, 2019|
|Forward Dividend & Yield||3.60 (2.79%)|
|1y Target Est||145.39|
Johnson & Johnson warns of sluggish sales in 2019. Yahoo Finance's Adam Shapiro, Emily McCormick, Rick Newman, Ethan Wolff-Mann and Tendayi Kapfidze LendingTree Chief Economist discuss.
Damien Conover of Morningstar weighs in on Johnson & Johnson's talcum powder controversy and its impact on the company. He also says the firm could use asset divestiture to boost earnings or revenues in 2019.
AbbVie (ABBV) is likely to beat earnings in fourth quarter. Impressive sales of its key drug, Humira and strong growth of Imbruvica and Mavyret are expected to drive fourth-quarter sales.
Johnson & Johnson is reportedly considering a bid for Auris Health, a privately held robotic surgery firm with a lung cancer biopsy tool that rivals Intuitive Surgical's not-yet-cleared Ion.
How Johnson & Johnson and Abbott Laboratories Stack Up(Continued from Prior Part)Margin guidance In its third-quarter earnings conference call, Johnson & Johnson (JNJ) has forecasted YoY improvement of at least 150 basis points in pre-tax
The NBCUniversal and CNBC parent reported adjusted quarterly profit of 64 cents per share, beating consensus estimates by 2 cents a share. United Technologies UTX – The maker of Carrier air conditioners, Otis elevators, and a wide variety of other industrial products reported adjusted quarterly profit of $1.95 per share, well above the consensus estimate of $1.53 a share. Revenue also came in above analysts' forecasts, boosted by the company's November acquisition of defense contractor Rockwell Collins.
J&J is seeking to purchase Auris at a premium to the valuation from its latest funding round that valued the company at $2 billion, Bloomberg reported. The final deal has not been reached and there is no certainty that the deliberations will lead to a sale of Auris, according to Bloomberg. J&J declined to comment while Auris could not be immediately reached for comment.
Johnson & Johnson is pursuing an acquisition of surgical robotics firm Auris Health Inc, Bloomberg reported on Wednesday, citing people with knowledge of the matter. J&J is seeking to purchase Auris at a premium to the valuation from its latest funding round that valued the company at $2 billion, Bloomberg reported https://bloom.bg/2RG9kwA. The final deal has not been reached and there is no certainty that the deliberations will lead to a sale of Auris, according to Bloomberg.
How Johnson & Johnson and Abbott Laboratories Stack Up(Continued from Prior Part)Earnings guidance In its third-quarter earnings conference call, Johnson & Johnson (JNJ) has forecasted its fiscal 2018 adjusted EPS to be $8.13–$8.18, which
The Tuesday slide also marked the first decline for the Dow, S&P 500, and Nasdaq in five sessions. Dow stock IBM (IBM) was jumping about 6 percent in premarket trading after the company reported adjusted quarterly profit of $4.87 per share, 5 cents above consensus. After-the-bell reports this afternoon will come from Citrix Systems (CTXS), Ford Motor (F), F5 Networks (FFIV), Las Vegas Sands (LVS), Texas Instruments (TXN), and Xilinx (XLNX).
Concerns about potential product liability from contamination of Johnson & Johnson’s baby powder sparked a nasty selloff in the company’s stock late last year. Fourth-quarter results from J&J on Tuesday highlight a more immediate risk: slowing growth. The range implies little or no sales growth this year and its shares fell in morning trading.